Indeed, inhibitors of ERK1/2 have already shown to efficiently inhibit MAPK signaling and proliferation of melanoma cells and their usefulness has been further evaluated in clinical trials (e.g. NCT01781429, NCT01875705) [24, 25]. The gene discussed is MAPK3; the disease is melanoma.